Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: JFitnich who wrote (5031)	12/6/1997 5:23:00 PM
From: aknahow	Respond to of 17367

JF, thanks for the input. I know institutional people like THESTREET and they have access to everything put out by their own firms. Their firms probably pay for the sub to thestreet but even so when you are told they think it's the best and you like Cramers style it's worth paying for. Again, I think it has future implications for XOMA. However there are two ifs. The frst is that Murphy's Biotech fund continue to perform well enough to get mentioned. The second is that Xoma itself at least not tank, in which case Murphy might still get mentioned and this would indirectly impact Xoma or best case that Xoma be one of principal reasons for Murphy's performance. In this case Xoma will get mentioned. Murphy's book comes out on the 29th. Free copies for new subscribers. Barrons ads for Sturza & Murphy right next to one another. Murphy no longer mentions his picks. Sturza ad mentions performance record for two yrs.